Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for JAMES A. COOKE
63.90
+0.06 (0.09%)
Real-time:   1:38PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.38 - 64.42
52 week 38.49 - 75.17
Open 64.04
Vol / Avg. 342,672.00/1.11M
Mkt cap 9.69B
P/E     -
Div/yield     -
EPS -0.25
Shares 148.48M
Beta 1.09
Inst. own 98%
Jul 27, 2015
Q2 2015 Alkermes Plc Earnings Release (Estimated) Add to calendar
Jun 23, 2015
Alkermes Plc Conference Call to Discuss Data of ALKS 3831 for Treatment of Schizophrenia - Webcast
Jun 9, 2015
Alkermes Plc at Goldman Sachs Healthcare Conference
Jun 1, 2015
Alkermes Plc at Jefferies Global Healthcare Conference
May 27, 2015
Alkermes Plc Annual Shareholders Meeting
May 18, 2015
Alkermes Plc at UBS Global Healthcare Conference
Apr 30, 2015
Q1 2015 Alkermes Plc Earnings Release
Apr 30, 2015
Q1 2015 Alkermes Plc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -19.02% -4.86%
Operating margin -16.94% -14.08%
EBITD margin - 1.77%
Return on average assets -6.39% -1.72%
Return on average equity -8.73% -2.44%
Employees 1,300 -
CDP Score - -

Address

Connaught House 1 Burlington Road, Dublin 4
DUBLIN, 00000
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Company's main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 56
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President, Corporate Communications
Age: 38
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters